The Joint Corp. Reports Fourth Quarter and Full Year 2019 Financial Results
Company Added
Company Removed
Apply to Request List

The Joint Corp. Reports Fourth Quarter and Full Year 2019 Financial Results

  • Grows Annual System-Wide Sales 33% and Comp Sales 25%, Compared to 2018
  • Increases Annual Net Income to $3.3 Million, Compared to $147,000 in 2018
  • More than Doubles Adjusted EBITDA to $6.2 Million, Compared to $2.9 Million in 2018
  • Increases Franchise Licenses Sales to 126, Compared to 99 in 2018
  • Targets 1,000 Clinics by End of 2023

SCOTTSDALE, Ariz., March 05, 2020 // GLOBE NEWSWIRE // - The Joint Corp. (NASDAQ: JYNT), a national operator, manager and franchisor of chiropractic clinics, reported its financial results for the fourth quarter and full year ended December 31, 2019.

Fourth Quarter Financial Highlights: 2018 Compared to 2019

  • Increased gross system-wide sales1 34%, to $62.5 million.
  • Grew system-wide comp sales2 26%.
  • Reported quarterly net income of $1.3 million, an improvement of $855,000.
  • Nearly doubled Adjusted EBITDA to $2.1 million, compared to $1.1 million.

Annual Financial Highlights: 2018 Compared to 2019

  • Increased annual system-wide sales1 33%, to $220.3 million.
  • Grew system-wide comp sales2 25%.
  • Posted annual net income of $3.3 million, compared to $147,000.
  • Achieved positive Adjusted EBITDA for the tenth consecutive quarter and second full year since being public.
  • More than doubled Adjusted EBITDA to $6.2 million, compared to $2.9 million.
  • Increased cash generated by operating activities by $2.1 million to $7.5 million, which funded the corporate clinic portfolio expansion. Unrestricted cash was $8.5 million at December 31, 2019, compared to $8.7 million at December 31, 2018.

2019 Operating Achievements

  • Performed 7.7 million patient visits, up from 6.0 million in 2018.
  • Treated 585,000 new patients, up from 435,000 in 2018.
  • Sold 126 franchise licenses in 2019, compared to 99 sold in 2018.
  • Increased total clinic count to 513 as of December 31, 2019: up from 442 at December 31, 2018.
    • 453 franchised clinics at December 31, 2019: Opened 71 and closed 4 clinics.
    • 60 company-owned or managed clinics at December 31, 2019: Acquired 8 from franchisees, opened 5 greenfields and closed 1 clinic. In February, opened the first 2020 greenfield, increasing the Los Angeles region cluster and bringing the corporate portfolio to 61 as of today, March 5, 2020. 

_______________________________

1 System-wide sales include sales at all clinics, whether operated by the Company or by franchisees. While franchised sales are not recorded as revenues by the Company, management believes the information is important in understanding the Company’s financial performance, because these sales are the basis on which the Company calculates and records royalty fees and are indicative of the financial health of the franchisee base. 
2 Comp sales include the sales from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed.

“In 2019, we accelerated our business momentum and continued to deliver strong, sustainable growth and profitability,” said Peter D. Holt, President and Chief Executive Officer of The Joint Corp. “We leveraged our regional developers to drive franchise sales and clinic openings as well as expanded our corporate clinic portfolio within clustered locations. We also continued to implement productivity initiatives to improve clinic profitability. As a result, we met or exceeded our plan, achieved positive Adjusted EBITDA for the second full consecutive year since being public, and built our strongest foundation for growth to date.”

“In addition to macro factors driving adoption of chiropractic care, The Joint is revolutionizing access making it more available to people than ever before. To capture a greater share of the market opportunity, we will continue to execute our successful growth model as well as test new markets and non-traditional locations. While focused on our national and local ad campaigns that include more sophisticated digital programs, we remain committed to consumer education about the power and importance of chiropractic. Based on our success, we fully expect to reach our target to open our 1,000th clinic by the end of 2023.”

Fourth Quarter Financial Results: 2019 Compared to 2018

Revenue was $13.9 million in the fourth quarter of 2019, compared to $10.0 million in the fourth quarter of 2018, with the increase due primarily to a greater number of and increased gross sales at franchised and company-owned or managed clinics.

Cost of revenue was $1.6 million, up 36% compared to the fourth quarter of 2018, reflecting the success of the RD program resulting in an increased number of franchised licenses sold and clinics opened, resulting in increased commissions and royalties.

Selling and marketing expenses were $1.8 million, or 13% of revenue, compared to $1.2 million, or 12% of revenue, in the fourth quarter of 2018, reflecting increased marketing expenses related to an increase in the number of company-owned or managed clinics. General and administrative expenses were $8.5 million, or 61% of revenue, compared to $6.6 million, or 66% of revenue, in the fourth quarter of 2018, reflecting improved leverage of the operating model.

Net income was $1.3 million, or $0.09 per diluted share, compared to a net income of $437,000, or $0.03 per diluted share, in the fourth quarter of 2018.

Adjusted EBITDA was $2.1 million, an improvement of $1.0 million, compared to Adjusted EBITDA of $1.1 million in the same quarter last year. The company defines Adjusted EBITDA, a non-GAAP measure, as EBITDA before acquisition-related expenses, bargain purchase gain, net (gain)/loss on disposition or impairment, and stock-based compensation expenses. The company defines EBITDA as net income/(loss) before net interest, tax expense, depreciation, and amortization expenses.

Balance Sheet Liquidity

Unrestricted cash was $8.5 million at December 31, 2019, compared to $8.7 million at December 31, 2018, reflecting increased cash flow from operations, which was more than offset by continued investment in corporate clinic expansion and the development of the new IT platform. In February, the company executed a $7.5 million senior secured credit facility with J.P. Morgan Chase Bank, including a $5.5 million development line of credit (LOC) and a $2.0 million revolving LOC, which has an uncommitted accordion feature for an additional $2.5 million.

Full Year Financial Results: 2019 Compared to 2018

Revenues were $48.5 million in 2019, compared to $36.7 million in 2018. Net income improved $3.2 million to $3.3 million in 2019, or to $0.23 per diluted share, compared to net income of $147,000, or $0.01 per diluted share in 2018. Adjusted EBITDA was $6.2 million, improving $3.3 million compared to Adjusted EBITDA of $2.9 million last year.

2020 Guidance for Financial Results and Clinic Openings:
Management expects the following:

  • Revenue to increase to $61 million to $63 million, compared to $48.5 million dollars in 2019.
  • Adjusted EBITDA to grow to $8.5 million to $9.5 million, compared to $6.2 million in 2019.
  • Franchised clinic openings to range from 80 to 90, compared to 71 clinics in 2019.
  • Company-owned or managed clinic expansion, through a combination of both greenfields and franchised clinic buybacks, to range from 16 to 20, up from 13 in 2019.

Conference Call

The Joint Corp. management will host a conference call at 5 p.m. ET on Thursday, March 5, 2020, to discuss the fourth quarter and year-end 2019 results. The conference call may be accessed by dialing 765-507-2604 or 844-464-3931 and referencing conference code 8090866. A live webcast of the conference call will also be available on the IR section of the company’s website at https://ir.thejoint.com/events. An audio replay will be available two hours after the conclusion of the call through March 12, 2020. The replay can be accessed by dialing 404-537-3406 or 855-859-2056. The passcode for the replay is 8090866.

Non-GAAP Financial Information

This release includes a presentation of non-GAAP financial measures. System-wide sales include sales at all clinics, whether operated by the Company or by franchisees. While franchised sales are not recorded as revenues by the Company, management believes the information is important in understanding the Company’s financial performance, because these sales are the basis on which the Company calculates and records royalty fees and are indicative of the financial health of the franchisee base. Comp sales include the sales from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed.

EBITDA and Adjusted EBITDA are presented because they are important measures used by management to assess financial performance, as management believes they provide a more transparent view of the company’s underlying operating performance and operating trends. Reconciliation of net income (loss) to EBITDA and Adjusted EBITDA is presented in the table below. The company defines Adjusted EBITDA as EBITDA before acquisition-related expenses, bargain purchase gain, net (gain)/loss on disposition or impairment, and stock-based compensation expenses. The company defines EBITDA as net income/(loss) before net interest, tax expense, depreciation, and amortization expenses.

EBITDA and Adjusted EBITDA do not represent and should not be considered alternatives to net income or cash flows from operations, as determined by accounting principles generally accepted in the United States, or GAAP. While EBITDA and Adjusted EBITDA are used as measures of financial performance and the ability to meet debt service requirements, they are not necessarily comparable to other similarly titled captions of other companies due to potential inconsistencies in the methods of calculation. EBITDA and Adjusted EBITDA should be reviewed in conjunction with the company’s financial statements filed with the SEC.

Forward-Looking Statements

This press release contains statements about future events and expectations that constitute forward-looking statements. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our growth plans, taking into account the information currently available to us. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the expectations of future results we express or imply in any forward-looking statements, and you should not place undue reliance on such statements. Factors that could contribute to these differences include, but are not limited to, our failure to develop or acquire company-owned or managed clinics as rapidly as we intend, our failure to profitably operate company-owned or managed clinics, uncertainties associated with the coronavirus (including its possible effects on patient demand), and the other factors described in “Risk Factors” in our Annual Report on Form 10-K as filed with the SEC for the year ended December 31, 2018, as updated for any material changes described in any subsequently-filed Quarterly Reports on Form 10-Q, and in our Annual Report on Form 10-K for the year ended December 31, 2019 expected to be filed with the SEC on or around March 6, 2020, as they may be revised or updated in our subsequent filings. Words such as, "anticipates," "believes," "continues," "estimates," "expects," "goal," "objectives," "intends," "may," "opportunity," "plans," "potential," "near-term," "long-term," "projections," "assumptions," "projects," "guidance," "forecasts," "outlook," "target," "trends," "should," "could," "would," "will," and similar expressions are intended to identify such forward-looking statements. We qualify any forward-looking statements entirely by these cautionary factors. We assume no obligation to update or revise any forward-looking statements for any reason or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.

About The Joint Corp. (NASDAQ: JYNT)

The Joint Corp. (NASDAQ: JYNT) revolutionized access to chiropractic care when it introduced its retail healthcare business model in 2010. Today, the company is making quality care convenient and affordable, while eliminating the need for insurance, for millions of patients seeking pain relief and ongoing wellness. With more than 500 locations nationwide and over 7 million patient visits annually, The Joint is a key leader in the chiropractic industry. Named on Franchise Times “Top 200+ Franchises” and Entrepreneur’s “Franchise 500®” lists, The Joint Chiropractic is an innovative force, where healthcare meets retail. For more information, visit www.thejoint.com. To learn about franchise opportunities, visit www.thejointfranchise.com.

Business Structure

The Joint Corp. is a franchisor of clinics and an operator of clinics in certain states. In Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Washington, West Virginia and Wyoming, The Joint Corp. and its franchisees provide management services to affiliated professional chiropractic practices.

Media Contact:

Margie Wojciechowski
Media Relations
The Joint Corp.
margie.wojciechowski@thejoint.com

Kirsten Chapman, LHA
Investor Relations
415-433-3777
thejoint@lhai.com

-Financial Tables Follow –
 
 
THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES
CONSOLIDATED BALANCE SHEETS
       
  December 31,   December 31,
    2019       2018  
ASSETS     (as adjusted)
Current assets:              
Cash and cash equivalents $ 8,455,989     $ 8,716,874  
Restricted cash   185,888       138,078  
Accounts receivable, net   2,645,085       806,350  
Income taxes receivable   -       268  
Notes receivable, net - current portion   128,724       149,349  
Deferred franchise costs - current portion   765,508       611,047  
Prepaid expenses and other current assets   1,122,478       882,022  
Total current assets   13,303,672       11,303,988  
Property and equipment, net   6,581,588       3,658,007  
Operating lease right-of-use asset   12,486,672       -  
Notes receivable, net of current portion   -       128,723  
Deferred franchise costs, net of current portion   3,627,225       2,878,163  
Intangible assets, net   3,219,791       1,634,060  
Goodwill   4,150,461       3,225,145  
Deposits and other assets   336,258       599,627  
Total assets $ 43,705,667     $ 23,427,713  
               
LIABILITIES AND STOCKHOLDERS' EQUITY              
Current liabilities:              
Accounts payable $ 1,525,838     $ 1,253,274  
Accrued expenses   216,814       266,322  
Co-op funds liability   185,889       104,057  
Payroll liabilities   2,844,107       2,035,658  
Notes payable - current portion   -       1,100,000  
Deferred rent - current portion   -       136,550  
Operating lease liability - current portion   2,313,109       -  
Finance lease liability - current portion   24,253       -  
Deferred franchise and regional developer fee revenue - current portion   2,740,954       2,370,241  
Deferred revenue from company clinics   3,196,664       2,529,497  
Other current liabilities   518,686       477,528  
Total current liabilities   13,566,314       10,273,127  
Deferred rent, net of current portion   -       721,730  
Operating lease liability - net of current portion   11,901,040       -  
Finance lease liability - net of current portion   34,398       -  
Deferred franchise and regional developer fee revenue, net of current portion   12,366,322       11,239,221  
Deferred tax liability   89,863       76,672  
Other liabilities   27,230       389,362  
Total liabilities   37,985,167       22,700,112  
Commitments and contingencies              
Stockholders' equity:              
Series A preferred stock, $0.001 par value; 50,000 shares authorized,              
0 issued and outstanding, as of December 31, 2019 and December 31, 2018   -       -  
Common stock, $0.001 par value; 20,000,000 shares              
authorized, 13,898,694 shares issued and 13,882,932 shares outstanding              
as of December 31, 2019 and 13,757,200 shares issued and 13,742,530              
outstanding as of December 31, 2018   13,899       13,757  
Additional paid-in capital   39,454,937       38,189,251  
Treasury stock 15,762 shares as of December 31, 2019 and 14,670 shares as of December 31, 2018, at cost   (111,041 )     (90,856 )
Accumulated deficit   (33,637,395 )     (37,384,651 )
Total The Joint Corp. stockholders' equity   5,720,400       727,501  
Non-controlling Interest   100       100  
Total equity   5,720,500       727,601  
Total liabilities and stockholders' equity $ 43,705,667     $ 23,427,713  
       

 

THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES
CONSOLIDATED STATEMENTS OF OPERATIONS
 
         
    Three Months Ended   Year Ended
    December 31,   December 31,
      2019       2018       2019       2018  
            (as adjusted)             (as adjusted)  
Revenues:                                
Revenues from company-owned or managed clinics   $ 7,561,644     $ 5,217,122     $ 25,807,584     $ 19,545,276  
Royalty fees     3,819,554       2,857,196       13,557,170       10,141,036  
Franchise fees     385,868       433,042       1,791,545       1,688,039  
Advertising fund revenue     1,086,479       778,475       3,884,055       2,862,244  
Software fees     609,068       342,500       1,865,779       1,290,135  
Regional developer fees     209,234       178,295       803,849       599,370  
Other revenues     203,322       161,591       740,918       535,560  
Total revenues     13,875,169       9,968,221       48,450,900       36,661,660  
Cost of revenues:                                
Franchise cost of revenues     1,525,381       1,100,818       5,159,778       3,956,530  
IT cost of revenues     108,578       100,808       406,139       353,719  
Total cost of revenues     1,633,959       1,201,626       5,565,917       4,310,249  
Selling and marketing expenses     1,845,124       1,228,993       6,913,709       4,819,555  
Depreciation and amortization     590,742       374,579       1,899,257       1,556,240  
General and administrative expenses     8,464,787       6,625,020       30,543,030       25,238,121  
Total selling, general and administrative expenses     10,900,653       8,228,592       39,355,996       31,613,916  
Net (gain) loss on disposition or impairment     (2,423 )     -       114,352       594,934  
Income from operations     1,342,980       538,003       3,414,635       142,561  
                                 
Other income (expense):                                
Bargain purchase gain     -       (17,258 )     19,298       13,198  
Other (expense), net     (18,046 )     (14,209 )     (61,515 )     (46,791 )
Total other (expense)     (18,046 )     (31,467 )     (42,217 )     (33,593 )
                                 
Income before income tax expense (benefit)     1,324,934       506,536       3,372,418       108,968  
                                 
Income tax expense (benefit)     33,110       69,847       48,706       (37,728 )
                                 
Net income and comprehensive income   $ 1,291,824     $ 436,689     $ 3,323,712     $ 146,696  
                                 
Less: income attributable to the non-controlling interest   $ -     $ -     $ -     $ -  
                                 
Net income attributable to The Joint Corp. stockholders   $ 1,291,824     $ 436,689     $ 3,323,712     $ 146,696  
                                 
Earnings per share:                                
Basic earnings per share   $ 0.09     $ 0.03     $ 0.24     $ 0.01  
Diluted earnings per share   $ 0.09     $ 0.03     $ 0.23     $ 0.01  
                                 
Basic weighted average shares     13,880,146       13,735,898       13,819,149       13,669,107  
Diluted weighted average shares     14,538,338       14,096,890       14,467,567       14,031,717  
                                 

 

THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES
 CONSOLIDATED STATEMENTS OF CASH FLOWS
 
                 
                 
    Year Ended
    December 31,
      2019       2018  
            (as adjusted)
Net income   $ 3,323,712     $ 146,696  
Adjustments to reconcile net income to net cash                
provided by operating activities     2,602,799       2,461,436  
Changes in operating assets and liabilities     1,595,438       2,844,136  
Net cash provided by operating activities     7,521,949       5,452,268  
Net cash used in investing activities     (7,138,062 )     (1,243,654 )
Net cash (used in) provided by financing activities     (596,962 )     326,298  
Net (decrease) increase in cash   $ (213,075 )   $ 4,534,912  
                 

 

THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES
RECONCILIATION FOR GAAP TO NON-GAAP
 
    Three Months Ended   Year Ended
    December 31,   December 31,
Non-GAAP Financial Data:     2019       2018     2019       2018  
        (as adjusted)     (as adjusted)
Net income   $ 1,291,824     $ 436,689   $ 3,323,712     $ 146,696  
Net interest     18,046       14,209     61,515       46,791  
Depreciation and amortization expense     590,742       374,579     1,899,257       1,556,240  
Tax expense (benefit)     33,110       69,847     48,706       (37,728 )
EBITDA   $ 1,933,722     $ 895,324   $ 5,333,190     $ 1,711,999  
Stock compensation expense     183,906       159,025     720,651       628,430  
Acquisition related expenses     11,145       -     47,386       3,950  
Bargain purchase gain     -       17,258     (19,298 )     (13,198 )
Net (gain) loss on disposition or impairment     (2,423 )     -     114,352       594,934  
Adjusted EBITDA   $ 2,126,350     $ 1,071,607   $ 6,196,281     $ 2,926,115  
                 

SOURCE The Joint Corp. (NASDAQ: JYNT)

###

Add to Request List

Comments:

comments powered by Disqus
Share This Page

Subscribe to Our Newsletters

A Franchise Update Media Production
Franchise Update Media
P.O. Box 20547
San Jose, CA 95160
PH. (408) 402-5681
In Loving Memory Of Timothy Gardner (1987-2014)

Copyright © 2001 - 2020.
All Rights Reserved.